FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760505248> ?p ?o ?g. }

• W2760505248 endingPage "E524" @default.
• W2760505248 startingPage "E523" @default.
• W2760505248 abstract "The anti-CTLA-4 and anti-programmed cell death-1 (PD-1) antibody therapies have significantly improved survival of patients with metastatic melanoma. However, little is known about the interaction of immunotherapy and stereotactic radiosurgery (SRS) for brain metastases and how the combination may affect toxicity and intracranial tumor control. We retrospectively reviewed 26 patients with 106 lesions who received immunotherapy and SRS for brain metastases from 2011-2016. 13 patients received Ipilimumab alone, 2 patients received Pembrolizumab alone, and the remaining patients received combination therapy. Treatment response was evaluated based on imaging and clinical follow-up. Treatment toxicities were recorded. To study the impact of timing and sequencing of immunotherapy on SRS, we categorized the lesions into two groups. The concurrent group included patients treated with SRS within 30 days of immunotherapy. The non-concurrent group included patients treated with SRS at least 30 days before or after immunotherapy. Kaplan-Meier methods were used to determine overall survival (OS), local control (LC) and regional control (RC). OS was analyzed per patient, from the date of diagnosis of brain metastasis to date of death or last patient contact. Local and regional recurrence-free duration were analyzed per treated lesion. Regional recurrence was defined as intracranial failure outside of the treatment field. The median follow-up was 14.5 (range 3 to 54) months. The median age was 59 (range 19-92) years. The median KPS and melanoma specific GPA were 80 and 2, respectively. Median survival was 26.1 months. The 1, 2 and 3 yr OS rates were 67%, 62%, and 45% respectively. The 1, 2 and 3 yr LC rates were 100%, 90% and 84%. The 1, 2, and 3 yr RC rates were 37%, 18% and 5%. 2.8% of the lesions developed a local recurrence. There was no difference in LC in SRS lesions treated with concurrent vs. non-concurrent immunotherapy. However, there was a significant improvement in regional recurrence free duration in lesions treated concurrently with immunotherapy compared to those treated without concurrent immunotherapy. The median regional recurrence-free duration was 15 mo vs 2 mo, P=0.0067. Treatment related adverse effects were noted in 35% of the SRS treated lesions, including focal neurologic deficits, seizure, headaches, and steroid dependence. No grade 4 or 5 toxicities were noted. SRS delivered concurrently with either single or dual check point blockade therapy is safe and well tolerated. The increased regional control following concurrent SRS and immunotherapy suggests radiotherapy may augment the regional effects of immunotherapy. Our findings may influence clinical decisions on how to optimize intracranial disease control to further improve treatment outcomes." @default.
• W2760505248 created "2017-10-06" @default.
• W2760505248 creator A5020882280 @default.
• W2760505248 creator A5034613490 @default.
• W2760505248 creator A5046389664 @default.
• W2760505248 creator A5047449097 @default.
• W2760505248 creator A5057413596 @default.
• W2760505248 creator A5070140716 @default.
• W2760505248 creator A5072111088 @default.
• W2760505248 creator A5086248029 @default.
• W2760505248 date "2017-10-01" @default.
• W2760505248 modified "2023-09-27" @default.
• W2760505248 title "Concurrent Radiosurgery and Immunotherapy is Associated with Improved Intracranial Tumor Control in Patients with Metastatic Melanoma" @default.
• W2760505248 doi "https://doi.org/10.1016/j.ijrobp.2017.06.1857" @default.
• W2760505248 hasPublicationYear "2017" @default.
• W2760505248 type Work @default.
• W2760505248 sameAs 2760505248 @default.
• W2760505248 citedByCount "1" @default.
• W2760505248 countsByYear W27605052482022 @default.
• W2760505248 crossrefType "journal-article" @default.
• W2760505248 hasAuthorship W2760505248A5020882280 @default.
• W2760505248 hasAuthorship W2760505248A5034613490 @default.
• W2760505248 hasAuthorship W2760505248A5046389664 @default.
• W2760505248 hasAuthorship W2760505248A5047449097 @default.
• W2760505248 hasAuthorship W2760505248A5057413596 @default.
• W2760505248 hasAuthorship W2760505248A5070140716 @default.
• W2760505248 hasAuthorship W2760505248A5072111088 @default.
• W2760505248 hasAuthorship W2760505248A5086248029 @default.
• W2760505248 hasConcept C121608353 @default.
• W2760505248 hasConcept C126322002 @default.
• W2760505248 hasConcept C141071460 @default.
• W2760505248 hasConcept C143998085 @default.
• W2760505248 hasConcept C2777658100 @default.
• W2760505248 hasConcept C2777701055 @default.
• W2760505248 hasConcept C2778164965 @default.
• W2760505248 hasConcept C2779013556 @default.
• W2760505248 hasConcept C2780030458 @default.
• W2760505248 hasConcept C2780057760 @default.
• W2760505248 hasConcept C2780387249 @default.
• W2760505248 hasConcept C2781433595 @default.
• W2760505248 hasConcept C502942594 @default.
• W2760505248 hasConcept C509974204 @default.
• W2760505248 hasConcept C71924100 @default.
• W2760505248 hasConceptScore W2760505248C121608353 @default.
• W2760505248 hasConceptScore W2760505248C126322002 @default.
• W2760505248 hasConceptScore W2760505248C141071460 @default.
• W2760505248 hasConceptScore W2760505248C143998085 @default.
• W2760505248 hasConceptScore W2760505248C2777658100 @default.
• W2760505248 hasConceptScore W2760505248C2777701055 @default.
• W2760505248 hasConceptScore W2760505248C2778164965 @default.
• W2760505248 hasConceptScore W2760505248C2779013556 @default.
• W2760505248 hasConceptScore W2760505248C2780030458 @default.
• W2760505248 hasConceptScore W2760505248C2780057760 @default.
• W2760505248 hasConceptScore W2760505248C2780387249 @default.
• W2760505248 hasConceptScore W2760505248C2781433595 @default.
• W2760505248 hasConceptScore W2760505248C502942594 @default.
• W2760505248 hasConceptScore W2760505248C509974204 @default.
• W2760505248 hasConceptScore W2760505248C71924100 @default.
• W2760505248 hasIssue "2" @default.
• W2760505248 hasLocation W27605052481 @default.
• W2760505248 hasOpenAccess W2760505248 @default.
• W2760505248 hasPrimaryLocation W27605052481 @default.
• W2760505248 hasRelatedWork W2607780130 @default.
• W2760505248 hasRelatedWork W2795840968 @default.
• W2760505248 hasRelatedWork W2903811712 @default.
• W2760505248 hasRelatedWork W2905838319 @default.
• W2760505248 hasRelatedWork W2915045061 @default.
• W2760505248 hasRelatedWork W2969738919 @default.
• W2760505248 hasRelatedWork W2972534027 @default.
• W2760505248 hasRelatedWork W3035446385 @default.
• W2760505248 hasRelatedWork W3215044659 @default.
• W2760505248 hasRelatedWork W4292373623 @default.
• W2760505248 hasVolume "99" @default.
• W2760505248 isParatext "false" @default.
• W2760505248 isRetracted "false" @default.
• W2760505248 magId "2760505248" @default.
• W2760505248 workType "article" @default.